Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with (131)I-MIP-1095

PURPOSE: Prostate-specific membrane antigen (PSMA)-targeting radioligand therapy (RLT) was introduced in 2011. The first report described the antitumor and side effects of a single dose. The aim of this analysis was to evaluate toxicity and antitumor activity after single and repetitive therapies. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Afshar-Oromieh, Ali, Haberkorn, Uwe, Zechmann, Christian, Armor, Thomas, Mier, Walter, Spohn, Fabian, Debus, Nils, Holland-Letz, Tim, Babich, John, Kratochwil, Clemens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5397661/
https://www.ncbi.nlm.nih.gov/pubmed/28280855
http://dx.doi.org/10.1007/s00259-017-3665-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5397661/
https://www.ncbi.nlm.nih.gov/pubmed/28280855
http://dx.doi.org/10.1007/s00259-017-3665-9

Ejemplares similares